Filter by

  • Publication Year
  • Availability
  • Attachment
  • Collection Type
    See More
  • General Material Designation
    See More
  • Location
    See More
  • Language
Found 5 from your keywords: subject="Fondaparinux"
cover
Use of fondaparinux in a patient with antiphospholipid antibody syndrome and …
Comment Share
HOLTAN SG

The diagnosis of antiphospholipid antibody syndrome (APS) requires one or more vascular thromboses in a patient with antiphospholipid antibodies or lupus anticoagulants detected in the blood on at least two occasions 6 weeks apart

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Efficacy and safety of fondaparinux for the prevention of venous thromboembol…
Comment Share
Cohen AT

To determine the efficacy and safety of the anticoagulant fondaparinux in older acute medical inpatients at moderate to high risk of venous thromboembolism

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Fondaparinux Sodium Compared With Low-Molecular-Weight Heparins for Periopera…
Comment Share
Kumar A

Fondaparinux sodium has been compared with low-molecular-weight heparins (LMWH) in randomized controlled trials for perioperative surgical thromboprophylaxis. However, the results from these studies are inconsistent in terms of efficacy and safety to reach a clinical decision. The objective of this study was to systematically review the randomized controlled trials comparing the efficacy and sa…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Veno…
Comment Share
Buller HR

The current standard initial therapies for deep venous thrombosis are low-molecular-weight heparin and unfractionated heparin. In a dose-ranging study of patients with symptomatic deep venous thrombosis, fondaparinux had efficacy and a safety profile similar to those of low-molecular-weight heparin (dalteparin)

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes
Comment Share
The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators*

The combined use of anticoagulants, antiplatelet agents, and invasive coronary procedures reduces ischemic coronary events but also increases bleeding in patients with acute coronary syndromes. We therefore assessed whether fondaparinux would preserve the anti-ischemic benefits of enoxaparin while reducing bleeding

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-